华熙生物(688363) - 2024 Q3 - 季度财报

Financial Performance - The company's operating revenue for Q3 2024 was ¥1,064,002,047.03, representing a decrease of 7.14% compared to the same period last year[2]. - The net profit attributable to shareholders for Q3 2024 was ¥20,258,275.61, down 77.44% year-on-year[2]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥10,583,321.09, a decrease of 85.37% compared to the previous year[2]. - The net cash flow from operating activities for Q3 2024 was ¥9,433,742.96, down 80.53% year-on-year[2]. - The basic earnings per share for Q3 2024 was ¥0.04, a decrease of 78.95% compared to the same period last year[3]. - Total operating revenue for the first three quarters of 2024 was approximately ¥3.87 billion, a decrease of 8.2% compared to ¥4.22 billion in the same period of 2023[14]. - Net profit for the first three quarters of 2024 was approximately ¥359 million, down 29.2% from ¥507 million in the same period of 2023[15]. - Operating profit for the first three quarters of 2024 was approximately ¥436 million, a decrease of 28.6% compared to ¥611 million in the same period of 2023[15]. - The basic earnings per share for the first three quarters of 2024 were ¥0.75, down from ¥1.07 in the same period of 2023[16]. Research and Development - The total R&D investment for Q3 2024 was ¥112,579,760.38, an increase of 24.52% year-on-year, accounting for 10.58% of operating revenue[3]. - Research and development expenses for the first three quarters of 2024 were approximately ¥313 million, an increase of 13.0% compared to ¥277 million in the same period of 2023[14]. Assets and Liabilities - The total assets at the end of the reporting period were ¥8,687,961,992.22, an increase of 2.57% compared to the end of the previous year[3]. - As of September 30, 2024, the total assets of the company amounted to RMB 8,687,961,992.22, an increase from RMB 8,470,008,293.83 at the end of 2023, reflecting a growth of approximately 2.58%[12]. - The company's total current liabilities decreased to RMB 1,136,227,866.53 from RMB 1,220,791,687.05, a reduction of approximately 6.9%[13]. - Total liabilities as of the end of the third quarter of 2024 were approximately ¥1.63 billion, an increase of 9.9% from ¥1.49 billion at the end of the third quarter of 2023[14]. - The company's total non-current assets reached RMB 6,005,480,452.74, up from RMB 5,347,153,037.58, reflecting an increase of about 12.2%[13]. Shareholder Information - The company reported a total of 32,273 common shareholders at the end of the reporting period[7]. - The largest shareholder, Huaxi Xinyu Investment Co., Ltd., held 58.86% of the shares[7]. - The company did not report any significant changes in the top 10 shareholders or their participation in margin trading activities during the reporting period[12]. Cash Flow - Cash flow from operating activities for the first three quarters of 2024 was approximately ¥4.18 billion, a decrease of 10.7% compared to ¥4.68 billion in the same period of 2023[17]. - Cash outflow from investment activities totaled approximately 953.74 million, a decrease from 1.85 billion in the previous period[19]. - Net cash flow from investment activities was negative at approximately -306.09 million, compared to -378.60 million last year[19]. - Cash inflow from financing activities was 100 million, an increase from 51.72 million in the previous period[19]. - Cash outflow from financing activities totaled approximately 449.70 million, slightly down from 465.54 million last year[19]. - Net cash flow from financing activities was negative at -349.70 million, compared to -413.83 million in the previous period[19]. - The ending balance of cash and cash equivalents was approximately 434.81 million, a decrease from 692.96 million in the previous period[19]. - The company's cash and cash equivalents decreased to RMB 511,521,498.37 from RMB 1,168,717,886.67, indicating a decline of about 56.3%[12]. Other Information - The company has adopted new accounting standards starting in 2024, which may affect financial reporting[20].